Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple MyelomaBusiness Wire • 08/19/21
3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over FistThe Motley Fool • 08/18/21
Got $100? Here Are 3 Top Dividend Growth Stocks to Jump-Start Your PortfolioThe Motley Fool • 08/17/21
EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 08/17/21
Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2Benzinga • 08/17/21
Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma IndustryBusiness Wire • 08/10/21
Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, SwitzerlandBusiness Wire • 08/03/21
Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric CancerBenzinga • 07/30/21
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following ChemoradiotherapyBusiness Wire • 07/30/21
